Proactiveinvestors interviews Bob Proulx on what FDA’s designation of MagSense® imaging as a “breakthrough device” means for the company and its investors:
https://youtu.be/X4HLKyIl6Zo
The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging
October 17, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the